Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access study of everolimus plus exemestane in postmenopausal women with endocrine-resistant advanced breast cancer
2012-000073-23Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of everolimus and exemestane in breast cancer and estrogen receptor-positive breast cancer, sponsored by Novartis. Primary endpoint: Frequency of adverse events and number of laboratory values that are new or worsening. Started Mar 2012; status: completed.
02
Drugs
everolimusexemestane
03
Conditions
breast cancerestrogen receptor-positive breast cancer
Beyond the preview
Go deeper on 2012-000073-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000073-23.